Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
- Status
- RECRUITING
- Phase
- N/A
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
- Status
- WITHDRAWN
- Phase
- PHASE2
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
- Status
- COMPLETED
- Phase
- PHASE4
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma
- Status
- UNKNOWN
- Phase
- NA
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
- Status
- COMPLETED
- Phase
- PHASE1
Treatment of Hematological Malignancy With Novel CAR-T Cells.
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Determining Normal Range for Free Light Chains in Serum Among Twins
- Status
- COMPLETED
- Phase
- NA
Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Status
- COMPLETED
- Phase
- PHASE1
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1